Conferences
EGA meeting London 2011: biosimilars competitiveness in the EU
At its 9th International Symposium on Biosimilar Medicines held in London, UK, on 14-15 April 2011 the European Generic medicines Association (EGA) highlighted the need for an EU industrial policy to enhance the competitiveness of biosimilars.
Pharmacokinetics, bioequivalence of cyclobenzaprine tablets
Cyclobenzaprine is a muscle relaxant, structurally related to first-generation tricyclic antidepressants. At the 2008 World Congress of Pharmacy and Pharmaceutical Sciences held 29 August – 4 September 2008 in Basel, Switzerland, Ms Tatiane Maria de Lima Souza Brioschi et al. of the University of Sao Paolo in Brazil presented a poster entitled ‘Pharmacokinetics and bioequivalence evaluation of cyclobenzaprine tablets’ in which the bioequivalence of two brands of cyclobenzaprine 10 mg tablets in healthy volunteers was evaluated.
Bioavailability and bioequivalence norms in Latin America
At the 2008 World Congress of Pharmacy and Pharmaceutical Sciences held 29 August – 4 September 2008 in Basel, Switzerland, Mr Luis Enrique Morena Exebio of the National Institutes of Health (NIH) in Peru, presented a poster entitled ‘Investigation’s ethical aspects regarding pharmaceutical products bioavailability and bioequivalence in Latin American legislation’.
Overcoming protein-production hurdles: Glycosylation
In a Genetic Engineering & Biotechnology News Feature Article of 1 June 2009, Mr John Morrow Jr discusses protein-production hurdles for biologicals, which was a key theme at IBC’s “Bioprocessing Meeting”, held in La Costa, CA, USA in 2009.
Overcoming protein-production hurdles: Expression systems
In a Genetic Engineering & Biotechnology News Feature Article of 1 June 2009, Mr John Morrow Jr discusses protein-production hurdles for biologicals, which was a key theme at IBC’s ‘Bioprocessing Meeting’, held in La Costa, CA, USA in 2009.
EGA meeting Barcelona 2009: Big Pharma must not underestimate generics
Big Pharma moving into generic medicines may seem like a shrewd move, but it is not necessarily a recipe for success, Ms Francesca Bruce of Scrip News heard at the European Generic medicines Association (EGA) conference recently held in Barcelona, Spain.
EGA: Biosimilars essential for generics industry as well
Would-be big generics players will have to move into biosimilars, Ms Francesca Bruce of Scrip News heard at the European Generic medicines Association (EGA) conference recently held in Barcelona, Spain.
EGA meeting Barcelona 2009: Will size matter in the generics space?
The generic medicines market is getting tougher and players of all sizes will find it harder to compete, but there are opportunities for both big and small firms, Ms Francesca Bruce of Scrip News heard at the recent European Generic medicines Association annual meeting in Barcelona, Spain.
EGA meeting Barcelona 2009: commoditisation risks sustainability of generic medicines market
The commoditisation of generic medicines markets could be a real threat to the sustainability of the industry, Ms Francesca Bruce of Scrip News heard at the European Generic medicines Association's (EGA) annual conference recently held in Barcelona, Spain.
Glycosylation main approval issue with biosimilars
Post-translational modifications (PTMs), particularly glycosylation, will play a critical role in how biosimilars – also called follow-on biologics or biogenerics – and will eventually be approved in the US. This stated science writer Mr Angelo DePalma in Genetic Engineering & Biotechnology News of 1 February 2009.
